{ "version": "2.2", "instance": { "zk2533581.htm exhibit_2.htm": { "nsprefix": "blrx", "nsuri": "http://biolinerx.com/20250630", "dts": { "schema": { "local": [ "blrx-20250630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/exch/2025/exch-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "blrx-20250630_cal.xml" ] }, "definitionLink": { "local": [ "blrx-20250630_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "blrx-20250630_lab.xml" ] }, "presentationLink": { "local": [ "blrx-20250630_pre.xml" ] }, "inline": { "local": [ "exhibit_2.htm", "zk2533581.htm" ] } }, "keyStandard": 95, "keyCustom": 52, "axisStandard": 7, "axisCustom": 0, "memberStandard": 8, "memberCustom": 11, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2025": 4 }, "contextCount": 73, "entityCount": 1, "segmentCount": 19, "elementCount": 375, "unitCount": 6, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 258, "http://xbrl.sec.gov/dei/2025": 13 }, "report": { "R1": { "role": "http://biolinerx.com/role/DocumentAndEntityInformation", "longName": "0001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2533581.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2533581.htm", "first": true, "unique": true } }, "R2": { "role": "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition", "longName": "0002 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_20250630", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20250630", "name": "ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "unique": true } }, "R3": { "role": "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss", "longName": "0003 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_20250401to20250630", "name": "ifrs-full:LicenceFeeIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250401to20250630", "name": "ifrs-full:LicenceFeeIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R4": { "role": "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity", "longName": "0004 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R5": { "role": "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements", "longName": "0005 - Statement - CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "unique": true } }, "R6": { "role": "http://biolinerx.com/role/GeneralInformation", "longName": "0006 - Disclosure - GENERAL INFORMATION", "shortName": "GENERAL INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R7": { "role": "http://biolinerx.com/role/BasisOfPreparation", "longName": "0007 - Disclosure - BASIS OF PREPARATION", "shortName": "BASIS OF PREPARATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R8": { "role": "http://biolinerx.com/role/SignificantAccountingPolicies", "longName": "0008 - Disclosure - MATERIAL ACCOUNTING POLICIES", "shortName": "MATERIAL ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R9": { "role": "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtig", "longName": "0009 - Disclosure - AT-THE-MARKET (\"ATM\") SALES AGREEMENT WITH HCW", "shortName": "AT-THE-MARKET (\"ATM\") SALES AGREEMENT WITH HCW", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "blrx:DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "blrx:DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R10": { "role": "http://biolinerx.com/role/CommitmentsAndContingentLiabilities", "longName": "0010 - Disclosure - CONTINGENT LIABILITIES", "shortName": "CONTINGENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R11": { "role": "http://biolinerx.com/role/EQUITYFINANCING", "longName": "0011 - Disclosure - FINANCINGS", "shortName": "FINANCINGS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "blrx:DisclosureOfEquityFinancingExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "blrx:DisclosureOfEquityFinancingExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R12": { "role": "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3", "longName": "0012 - Disclosure - FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3)", "shortName": "FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R13": { "role": "http://biolinerx.com/role/ShareholdersEquity", "longName": "0013 - Disclosure - SHAREHOLDERS' EQUITY", "shortName": "SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R14": { "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformation", "longName": "0014 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R15": { "role": "http://biolinerx.com/role/MATERIALACCOUNTINGPOLICIESPolicies", "longName": "9960701 - Disclosure - MATERIAL ACCOUNTING POLICIES (Policies)", "shortName": "MATERIAL ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "15", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "blrx:DescriptionOfAccountingPolicyForGeneralDisclosuresExplanatoryPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "blrx:DescriptionOfAccountingPolicyForGeneralDisclosuresExplanatoryPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R16": { "role": "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Tables", "longName": "9960702 - Disclosure - FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3) (Tables)", "shortName": "FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R17": { "role": "http://biolinerx.com/role/ShareholdersEquityTables", "longName": "9960703 - Disclosure - SHAREHOLDERS' EQUITY (Tables)", "shortName": "SHAREHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R18": { "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables", "longName": "9960704 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "C_20250101to20250630", "name": "blrx:DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630", "name": "blrx:DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R19": { "role": "http://biolinerx.com/role/GENERALINFORMATIONNarrativeDetails", "longName": "9960705 - Disclosure - GENERAL INFORMATION (Narrative) (Details)", "shortName": "GENERAL INFORMATION (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "C_20250630", "name": "ifrs-full:RetainedEarnings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "longName": "9960706 - Disclosure - AT-THE-MARKET (\"ATM\") SALES AGREEMENT WITH HCW (Narrative) (Details)", "shortName": "AT-THE-MARKET (\"ATM\") SALES AGREEMENT WITH HCW (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "C_20250630_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHcwMember", "name": "blrx:AggregateOfferingPrice", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "div", "div", "div", "div", "div", "div", "div", "blrx:DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20250101to20250630_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHcwMember", "name": "blrx:GrossProceedsFromIssuingShares", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "div", "div", "div", "div", "div", "div", "div", "blrx:DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "unique": true } }, "R21": { "role": "http://biolinerx.com/role/CONTINGENTLIABILITIESDeatils", "longName": "9960707 - Disclosure - CONTINGENT LIABILITIES (Narrative) (Details)", "shortName": "CONTINGENT LIABILITIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "C_20240601to20240630_ifrsfullCategoriesOfRelatedPartiesAxis_blrxBiokineTherapeuticsLtdMember", "name": "blrx:LawsuitClaimAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240601to20240630_ifrsfullCategoriesOfRelatedPartiesAxis_blrxBiokineTherapeuticsLtdMember", "name": "blrx:LawsuitClaimAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R22": { "role": "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "longName": "9960708 - Disclosure - FINANCINGS (Narrative) (Details)", "shortName": "FINANCINGS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxHighbridgeCapitalManagementLlcMember", "name": "blrx:SharesIssuedRegisteredDirectOfferings", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "div", "blrx:DisclosureOfEquityFinancingExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxHighbridgeCapitalManagementLlcMember", "name": "blrx:SharesIssuedRegisteredDirectOfferings", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "div", "blrx:DisclosureOfEquityFinancingExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R23": { "role": "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details", "longName": "9960709 - Disclosure - FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3) (Details)", "shortName": "FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "C_20241231", "name": "blrx:Warrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember_ifrsfullMeasurementAxis_ifrsfullAtFairValueMember", "name": "blrx:Warrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "unique": true } }, "R24": { "role": "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails", "longName": "9960710 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details)", "shortName": "SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "C_20250630", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20250630", "name": "blrx:AuthorizedShareCapitalValue", "unitRef": "ILS", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "unique": true } }, "R25": { "role": "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative", "longName": "9960711 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Narrative) (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "C_20250630_ifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis_ifrsfullSellingGeneralAndAdministrativeExpenseMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxGloriaBiosciencesMember", "name": "ifrs-full:AmountsReceivableRelatedPartyTransactions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250630_ifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis_ifrsfullSellingGeneralAndAdministrativeExpenseMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxGloriaBiosciencesMember", "name": "ifrs-full:AmountsReceivableRelatedPartyTransactions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R26": { "role": "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails", "longName": "9960712 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Schedule of Cost of revenues) (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Schedule of Cost of revenues) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_20250401to20250630", "name": "blrx:CostRelatedToLicenseRevenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250401to20250630", "name": "blrx:CostRelatedToLicenseRevenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } } }, "tag": { "ifrs-full_AccumulatedOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } } }, "auth_ref": [ "r262" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r190" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r203" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r203" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r203" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r203" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "totalLabel": "WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF EARNINGS (LOSS) PER SHARE - DILUTED", "terseLabel": "LOSS PER ORDINARY SHARE \u2013 DILUTED", "verboseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF EARNINGS (LOSS) PER ORDINARY SHARE - DILUTED" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r10" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "verboseLabel": "Decrease (increase) in inventory" } } }, "auth_ref": [ "r253" ] }, "blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in prepaid expense other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities.", "negatedLabel": "Decrease (increase) in prepaid expenses and other receivables", "label": "Adjustments For Decrease Increase In Prepaid Expenses And Other Operating Receivables" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "verboseLabel": "Decrease (increase) in trade receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r255" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Fair value adjustments of warrants" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilities", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in contract liabilities", "verboseLabel": "Decrease in contract liabilities" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade accounts payable", "terseLabel": "Decrease in accounts payable and accruals" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLoss", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss)", "terseLabel": "Adjustments required to reflect net cash used in operating activities (see appendix below)", "totalLabel": "Total Adjustments required to reflect net cash used in operating acivities" } } }, "auth_ref": [ "r19" ] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "verboseLabel": "Share-based compensation" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Exchange differences on cash and cash equivalents" } } }, "auth_ref": [ "r132", "r254" ] }, "blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments Required To Reflect Net Cash Used In Operating Activities [Abstract]", "verboseLabel": "Adjustments required to reflect net cash used in operating activities:" } } }, "auth_ref": [] }, "blrx_AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "AggregateOfferingPrice", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate offering price.", "label": "Aggregate offering price", "verboseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r247" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r163", "r173", "r183", "r214" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r166", "r176", "r186", "r217" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r248" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r203" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r210" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r167", "r177", "r187", "r210", "r218", "r222", "r230" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r228" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "blrx_AmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "AmericanDepositarySharesMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "ADSs [Member]", "label": "American Depositary Shares Member", "terseLabel": "ADSs [Member]" } } }, "auth_ref": [] }, "blrx_AmericanDepositarySharesSold": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "AmericanDepositarySharesSold", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of american depositary shares sold", "label": "American Depositary Shares Sold", "verboseLabel": "Number of American depositary shares sold" } } }, "auth_ref": [] }, "ifrs-full_AmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmortisationExpense", "crdr": "debit", "calculation": { "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails": { "parentTag": "ifrs-full_CostOfSales", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Amortisation expense", "negatedLabel": "Depreciation and amortisation expense", "totalLabel": "Total depreciation and amortisation expense", "verboseLabel": "Amortization of intangible asset in respect of license revenues" } } }, "auth_ref": [ "r261" ] }, "blrx_AmountAllocatedToWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "AmountAllocatedToWarrant", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount allocated to warrant.", "label": "Amount allocated to warrant", "verboseLabel": "Amount allocated to warrant" } } }, "auth_ref": [] }, "blrx_AmountOfFairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "AmountOfFairValueAdjustmentOfWarrants", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Amount Of Fair Value Adjustment Of Warrants", "documentation": "Represent the amount of fair value adjustment of warrants.", "terseLabel": "Amount of fair value adjustment of warrants" } } }, "auth_ref": [] }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsReceivableRelatedPartyTransactions", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative" ], "lang": { "en-us": { "role": { "label": "Amounts receivable, related party transactions", "terseLabel": "Outstanding payment receivable" } }, "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r4", "r7", "r77" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets [Default Label]", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r36", "r37", "r39", "r58", "r61", "r94", "r95", "r114" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "ifrs-full_AtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AtFairValueMember", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "At fair value [member]" } }, "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } } }, "auth_ref": [ "r16", "r17", "r28", "r36", "r86", "r93", "r94" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r259", "r261" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r259", "r261" ] }, "blrx_AuthorizedShareCapitalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "AuthorizedShareCapitalValue", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of authorized share capital.", "label": "Authorized Share Capital Value", "verboseLabel": "Authorized share capital" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r225" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r226" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r221" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r221" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r221" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r221" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r221" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r221" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r224" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r223" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r222" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r222" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic earnings (loss) per share", "verboseLabel": "EARNINGS (LOSS) PER ORDINARY SHARE - BASIC" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r8", "r9" ] }, "blrx_BeneficiallyOwnInExcess": { "xbrltype": "percentItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "BeneficiallyOwnInExcess", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Beneficially Own In Excess", "documentation": "Represent information about the beneficially own in excess.", "terseLabel": "Beneficially own in excess" } } }, "auth_ref": [] }, "blrx_BiokineTherapeuticsLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "BiokineTherapeuticsLtdMember", "presentation": [ "http://biolinerx.com/role/CONTINGENTLIABILITIESDeatils" ], "lang": { "en-us": { "role": { "label": "Biokine Therapeutics Ltd [Member]", "documentation": "Biokine Therapeutics Ltd." } } }, "auth_ref": [] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r262" ] }, "ifrs-full_CapitalReserveMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalReserveMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Capital reserve [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing capital reserves." } } }, "auth_ref": [ "r260" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements", "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r22", "r35", "r73", "r113" ] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Investments in short-term deposits" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r251" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash provided by financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r18", "r23" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS - FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash provided by (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r18", "r23" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS - INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "auth_ref": [ "r18", "r23" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS - OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "http://biolinerx.com/role/CONTINGENTLIABILITIESDeatils", "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]", "verboseLabel": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6", "r79" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "http://biolinerx.com/role/CONTINGENTLIABILITIESDeatils", "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r6", "r79" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r201" ] }, "ifrs-full_ChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInEquityAbstract", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "CHANGES FOR", "terseLabel": "CHANGES FOR THE PERIOD:" } } }, "auth_ref": [] }, "blrx_ChangesInFairValueRecordedAsANonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ChangesInFairValueRecordedAsANonoperatingIncome", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss.", "label": "Changes In Fair Value Recorded As A Non-operating Income", "terseLabel": "Changes in fair value recorded as non-operating income" } } }, "auth_ref": [] }, "blrx_ChangesInFairValueThroughProfitOrLossWarrantsMeasured": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ChangesInFairValueThroughProfitOrLossWarrantsMeasured", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Changes In Fair Value Through Profit Or Loss Warrants Measured", "documentation": "Net changes in fair value recognized in profit or loss for warrants.", "terseLabel": "Changes in fair value through profit and loss" } } }, "auth_ref": [] }, "blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Changes In Operating Assets And Liabilities [Abstract]", "verboseLabel": "Changes in operating asset and liability items:" } } }, "auth_ref": [] }, "blrx_ChangesInRightOfUseAssetAndLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ChangesInRightOfUseAssetAndLeaseLiabilities", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Changes in right-of-use asset and lease liabilities.", "label": "Changes In Right Of Use Asset And Lease Liabilities", "terseLabel": "Changes in right-of-use asset and lease liabilities", "verboseLabel": "Acquisition of right-of-use asset" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r198" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r196" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r53", "r54", "r55", "r56", "r91", "r92" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r53", "r54", "r55", "r56", "r91", "r92" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r202" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r202" ] }, "blrx_CommitmentsAndContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "CommitmentsAndContingentLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Commitment and contingent liabilities.", "label": "COMMITMENTS AND CONTINGENT LIABILITIES", "terseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r207" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r206" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r208" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r205" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r107" ] }, "blrx_CostOfProductSales": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "CostOfProductSales", "crdr": "debit", "calculation": { "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails": { "parentTag": "ifrs-full_CostOfSales", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Cost Of Product Sales", "documentation": "Cost of product sales.", "verboseLabel": "Cost of product sales" } } }, "auth_ref": [] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_GrossProfit", "weight": -1.0, "order": 0.0 }, "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss", "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "COST OF REVENUES", "label": "Cost of sales", "totalLabel": "Cost of revenues", "verboseLabel": "Cost of sales", "negatedTerseLabel": "Cost of sales" } } }, "auth_ref": [ "r103", "r127" ] }, "blrx_CostRelatedToLicenseRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "CostRelatedToLicenseRevenues", "crdr": "debit", "calculation": { "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails": { "parentTag": "ifrs-full_CostOfSales", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Cost Related To License Revenues", "verboseLabel": "Cost related to license revenues", "documentation": "Cost related to license revenues." } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Currency [Axis]", "verboseLabel": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r29", "r115", "r133" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current maturities of long-term loan" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r262" ] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current contract liabilities", "verboseLabel": "Contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r42" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Current maturities of lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r44" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r31", "r116", "r133" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r261" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r155", "r241" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r155", "r241" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r157", "r243" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r157", "r243" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r159", "r245" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r157", "r243" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r150", "r236" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r151", "r237" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r151", "r237" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r149", "r235" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r149", "r235" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r149", "r235" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r152", "r238" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r154", "r240" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r154", "r240" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r155", "r241" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r158", "r244" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r156", "r242" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r153", "r239" ] }, "blrx_DayOneLossOnWarrantsMeasured": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DayOneLossOnWarrantsMeasured", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Day One Loss On Warrants Measured", "documentation": "Initial loss recognized at issuance of warrants.", "terseLabel": "Day One loss" } } }, "auth_ref": [] }, "blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory", "presentation": [ "http://biolinerx.com/role/MATERIALACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "label": "Description Of Accounting Policy For Change In Accounting Policy And Disclosures Explanatory", "terseLabel": "New International Financial Reporting Standards, amendments to standards and new interpretations", "documentation": "The description of the entity's accounting policy for changes in accounting policies and disclosures.", "verboseLabel": "New international financial reporting standards, amendments to standards and new interpretations" } } }, "auth_ref": [] }, "blrx_DescriptionOfAccountingPolicyForGeneralDisclosuresExplanatoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DescriptionOfAccountingPolicyForGeneralDisclosuresExplanatoryPolicyTextBlock", "presentation": [ "http://biolinerx.com/role/MATERIALACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "label": "Description Of Accounting Policy For General Disclosures Explanatory [Policy Text Block]", "documentation": "The description of the entity's accounting policy for general disclosures.", "terseLabel": "General" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility (%)", "verboseLabel": "Average standard deviation" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r49" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate (%)", "verboseLabel": "Risk-free interest rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r49" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "commentaryGuidance": "The reported value should be tagged twice, with both this element and the element \u2018Basic earnings (loss) per share\u2019 when: (a) basic and diluted earnings per share are equal; and (b) an entity presents one line item to accomplish the dual presentation requirement of paragraph 67 of IAS 33.", "label": "Diluted earnings (loss) per share", "totalLabel": "Total diluted earnings (loss) per share", "verboseLabel": "EARNINGS (LOSS) PER ORDINARY SHARE - DILUTED" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r8", "r9" ] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } } }, "auth_ref": [ "r259", "r261" ] }, "blrx_DisclosureOfBasisOfPreparationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DisclosureOfBasisOfPreparationAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://biolinerx.com/role/BasisOfPreparation" ], "lang": { "en-us": { "role": { "label": "BASIS OF PREPARATION" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share Capital", "verboseLabel": "Schedule of Share Capital is Composed of Ordinary Shares" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r70", "r99", "r120" ] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block]", "verboseLabel": "CONTINGENT LIABILITIES" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesLineItems", "presentation": [ "http://biolinerx.com/role/CONTINGENTLIABILITIESDeatils" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesTable", "presentation": [ "http://biolinerx.com/role/CONTINGENTLIABILITIESDeatils" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } } }, "auth_ref": [ "r13", "r83" ] }, "blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Detailed Information About Cost Of Revenues Explanatory", "verboseLabel": "Schedule of Cost of Revenues", "documentation": "The disclosure of detailed information about cost of revenues." } } }, "auth_ref": [] }, "blrx_DisclosureOfEquityFinancingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DisclosureOfEquityFinancingAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Equity Financing [Abstract]" } } }, "auth_ref": [] }, "blrx_DisclosureOfEquityFinancingExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DisclosureOfEquityFinancingExplanatoryTextBlock", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCING" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Equity Financing Explanatory [Text Block]", "documentation": "The entire disclosure of equity financing.", "terseLabel": "FINANCINGS" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementExplanatory", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement [text block]", "terseLabel": "FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3)" } }, "en": { "role": { "documentation": "The entire disclosure for fair value measurement." } } }, "auth_ref": [ "r41" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of liabilities." } } }, "auth_ref": [ "r40", "r96" ] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://biolinerx.com/role/GeneralInformation" ], "lang": { "en-us": { "role": { "label": "GENERAL INFORMATION" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r67", "r109" ] }, "blrx_DisclosureOfGeneralInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DisclosureOfGeneralInformationAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of general information [Abstract]", "verboseLabel": "General Information Narrative" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assumptions Used to Value Options" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r50" ] }, "blrx_DisclosureOfIssuancesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DisclosureOfIssuancesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Issuances Of Share Capital [Abstract]", "verboseLabel": "Disclosure of issuances of share capital and warrants [Abstract]" } } }, "auth_ref": [] }, "blrx_DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtig" ], "lang": { "en-us": { "role": { "documentation": "Disclosure Of At The Market Atm Sales Agreement With Btig Explanatory .", "label": "Disclosure Of Market Atm Sales Agreement With Btig Explanatory", "terseLabel": "AT-THE-MARKET (\u201cATM\u201d) SALES AGREEMENT WITH HCW", "verboseLabel": "AT-THE-MARKET (\"ATM\") SALES AGREEMENT WITH BTIG" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES", "terseLabel": "MATERIAL ACCOUNTING POLICIES" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r74", "r101", "r108" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Amounts Outstanding Under Employee Share Incentive Plan" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r46", "r89" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Options Outstanding by Exercise Price Range" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r47" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://biolinerx.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "SHAREHOLDERS' EQUITY" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r71", "r100", "r121" ] }, "blrx_DisclosureOfSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DisclosureOfSignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of significant accounting policies [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Tables" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]", "terseLabel": "Schedule of Significant Unobservable Inputs Used in Fair Value Measurement of Liabilities" } }, "en": { "role": { "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities." } } }, "auth_ref": [ "r38" ] }, "blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DisclosureOfSupplementaryFinancialStatementInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplementary Financial Statement Information Schedule Of Other Receivables", "documentation": "Disclosure of supplimentry financial statements information.", "label": "Disclosure of supplementary financial statement information [Abstract]", "verboseLabel": "Supplementary Financial Statement Information" } } }, "auth_ref": [] }, "blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplementary financial statement information.", "terseLabel": "SUPPLEMENTAL FINANCIAL INFORMATION", "label": "Disclosure Of Supplementary Financial Statement Information Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r48", "r90" ] }, "blrx_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "DocumentAndEntityInformationAbstract", "lang": { "en-us": { "role": { "label": "Document And Entity Information [Abstract]", "verboseLabel": "Document And Entity Information" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r200" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r20", "r21" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "blrx_EmployeeStockOptionsForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "EmployeeStockOptionsForfeiture", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Employee Stock Options Forfeiture", "documentation": "Represent the amount of Employee stock options forfeiture", "verboseLabel": "Employee stock options forfeiture", "negatedLabel": "Employee stock options forfeiture" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r147" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r147" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r147" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r147" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r147" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r194" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r246" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r246" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r246" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition", "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "periodEndLabel": "BALANCE", "periodStartLabel": "BALANCE", "label": "Equity", "totalLabel": "Total equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r24", "r26", "r36", "r37", "r39", "r80", "r87", "r94", "r95", "r102", "r114", "r117" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "EQUITY" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r114" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities and equity" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r204" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r163", "r173", "r183", "r214" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r160", "r170", "r180", "r211" ] }, "blrx_ExchangeDifferencesOnLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ExchangeDifferencesOnLeaseLiability", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Exchange Differences On Lease Liability.", "label": "Exchange differences on lease liability", "terseLabel": "Exchange differences on lease liabilities" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r210" ] }, "blrx_ExercisePriceOfShareIssued": { "xbrltype": "perShareItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ExercisePriceOfShareIssued", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price of shares issued.", "label": "Exercise Price Of Share Issued", "verboseLabel": "Share price per ADS", "terseLabel": "Exercise price of shares issued" } } }, "auth_ref": [] }, "blrx_ExercisePriceOfWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ExercisePriceOfWarrants", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price of warrants.", "label": "Exercise price of warrants", "verboseLabel": "Exercise price of warrants" } } }, "auth_ref": [] }, "blrx_FairValueOfOrdinaryWarrantsAdjustedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "FairValueOfOrdinaryWarrantsAdjustedAmount", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Of Ordinary Warrants Adjusted Amount", "documentation": "Fair value of ordinary warrants adjusted amount.", "terseLabel": "Fair value of the ordinary warrants was adjusted amount" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "FINANCIAL EXPENSES", "label": "Finance costs" } } }, "auth_ref": [ "r125" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "FINANCIAL INCOME" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of the warrants" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r52" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r167", "r177", "r187", "r218" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r167", "r177", "r187", "r218" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r167", "r177", "r187", "r218" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r167", "r177", "r187", "r218" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r167", "r177", "r187", "r218" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r199" ] }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Change in fair value", "verboseLabel": "Change in fair value" } }, "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r264" ] }, "blrx_GloriaBiosciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "GloriaBiosciencesMember", "presentation": [ "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative" ], "lang": { "en-us": { "role": { "label": "Gloria Biosciences [Member]", "documentation": "Gloria Biosciences [Member]" } } }, "auth_ref": [] }, "blrx_GrossProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "GrossProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "documentation": "The gross cash inflow from issuing shares after deducting fees and expenses.", "label": "Gross Proceeds From Issuing Shares", "terseLabel": "Gross proceeds from issuing shares" } } }, "auth_ref": [] }, "blrx_GrossProceedsFromSharesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "GrossProceedsFromSharesIssued", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Gross Proceeds From Shares Issued", "documentation": "Gross proceeds from shares issued.", "verboseLabel": "Gross proceeds", "terseLabel": "Issuance of share capital and warrants, net of issuance costs" } } }, "auth_ref": [] }, "ifrs-full_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Gross profit", "totalLabel": "GROSS PROFIT" } } }, "auth_ref": [ "r140" ] }, "blrx_HcwMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "HcwMember", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for H.C. Wainwright & Co., LLC (\u201cHCW\u201d).", "label": "Hcw [Member]", "terseLabel": "HCW [Member]" } } }, "auth_ref": [] }, "blrx_HighbridgeCapitalManagementLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "HighbridgeCapitalManagementLlcMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Highbridge Capital Management Llc [Member]", "documentation": "Highbridge Capital Management LLC [Member]" } } }, "auth_ref": [] }, "blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "IncomeAndExpensesNotInvolvingCashFlowsAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Income And Expenses Not Involving Cash Flows [Abstract]", "verboseLabel": "Income and expenses not involving cash flows:" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r22", "r73" ] }, "blrx_IncreaseDecreaseThoughPreFundedWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "IncreaseDecreaseThoughPreFundedWarrantsExercised", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase Decrease Though Pre Funded Warrants Exercised", "documentation": "The increase (decrease) through in equity resulting from the pre funded warrants exercised.", "verboseLabel": "Pre-funded warrants exercised" } } }, "auth_ref": [] }, "blrx_IncreaseDecreaseThroughExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "IncreaseDecreaseThroughExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents the value of warrants exercised.", "label": "Increase Decrease Through Exercise Of Warrants", "verboseLabel": "Warrants exercised" } } }, "auth_ref": [] }, "blrx_IncreaseDecreaseThroughExpiredOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "IncreaseDecreaseThroughExpiredOfOptions", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the expiration of options.", "label": "Increase Decrease Through Expired Of Options", "verboseLabel": "Employee stock options expired" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share-based compensation" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r106" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r167", "r177", "r187", "r210", "r218", "r222", "r230" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r228" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r148", "r234" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r148", "r234" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r148", "r234" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r14", "r84", "r111" ] }, "blrx_InterestAndExchangeDifferencesOnShortTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "InterestAndExchangeDifferencesOnShortTermDeposits", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Interest and exchange differences on short-term deposits.", "label": "Interest And Exchange Differences On Short Term Deposits", "terseLabel": "Interest on short-term deposits", "verboseLabel": "Interest and exchange differences on short-term deposits" } } }, "auth_ref": [] }, "blrx_InterestOnLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "InterestOnLoans", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Interest on loans.", "label": "Interest on loans", "terseLabel": "Interest on loan" } } }, "auth_ref": [] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current inventories", "verboseLabel": "Inventory" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r2", "r72", "r112", "r142" ] }, "ifrs-full_InvestmentPropertyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentPropertyMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Investment property [member]" } }, "en": { "role": { "documentation": "This member stands for investment property. [Refer: Investment property]" } } }, "auth_ref": [ "r134", "r135" ] }, "blrx_IsraelNewShekelsMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "IsraelNewShekelsMember", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "NIS [Member]", "label": "Israel New Shekels [Member]", "verboseLabel": "NIS [Member]" } } }, "auth_ref": [] }, "blrx_IssuanceCostOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "IssuanceCostOfWarrants", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Issuance Cost Of Warrants", "documentation": "Represent the amount of Issuance cost of warrants", "verboseLabel": "Warrant issuance costs" } } }, "auth_ref": [] }, "blrx_IssuanceOfShareCapitalAndWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "IssuanceOfShareCapitalAndWarrantsNet", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents the value of shares and warrants issued.", "label": "Issuance Of Share Capital And Warrants, Net", "verboseLabel": "Issuance of share capital and warrants, net" } } }, "auth_ref": [] }, "blrx_IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issuance Of Share Capital Pre Funded Warrants And Warrants Net", "documentation": "Represents the value of share capital, pre-funded warrants and warrants issued.", "verboseLabel": "Issuance of share capital, pre-funded warrants and warrants, net" } } }, "auth_ref": [] }, "blrx_IssuancesOfWarrantsMeasured": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "IssuancesOfWarrantsMeasured", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Issuances Of Warrants Measured", "documentation": "Value of warrants issued during the period.", "terseLabel": "Issuances" } } }, "auth_ref": [] }, "blrx_IssuedAndPaidUpShareCapitalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "IssuedAndPaidUpShareCapitalValue", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of issued and paid up share capital.", "label": "Issued And Paid Up Share Capital Value", "verboseLabel": "Issued and paid-up share capital" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Ordinary shares" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r138", "r145" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Ordinary shares [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r107" ] }, "blrx_January2025OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "January2025OfferingMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "January 2025 Offering [Member]", "documentation": "January 2025 Offering [Member]" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Compensation cost", "totalLabel": "Benefits to key executive personnel" } } }, "auth_ref": [ "r3", "r76" ] }, "blrx_LawsuitClaimAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "LawsuitClaimAmount", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/CONTINGENTLIABILITIESDeatils" ], "lang": { "en-us": { "role": { "label": "Lawsuit Claim Amount", "documentation": "lawsuit claim amount", "verboseLabel": "Lawsuit claim amount" } } }, "auth_ref": [] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "terseLabel": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r11", "r12", "r37", "r82", "r95" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r1", "r37", "r95" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r1", "r37", "r95" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r36", "r37", "r39", "r58", "r62", "r94", "r95", "r114" ] }, "ifrs-full_LicenceFeeIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LicenceFeeIncome", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Licence fee income", "terseLabel": "License revenues" } } }, "auth_ref": [ "r261" ] }, "blrx_MaturitiesOfShortTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "MaturitiesOfShortTermDeposits", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Maturities of short-term deposits.", "negatedLabel": "Maturities of short-term deposits", "label": "Maturities Of Short Term Deposits" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r202" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r202" ] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r16", "r17", "r36", "r86", "r94" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r16", "r17", "r36", "r86", "r94" ] }, "blrx_MiscellaneousOtherComprehensiveLossMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "MiscellaneousOtherComprehensiveLossMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Other comprehensive loss [Member]", "label": "Miscellaneous Other Comprehensive Loss [Member]", "verboseLabel": "Other comprehensive loss [Member]" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r221" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r229" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r203" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r202" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r167", "r177", "r187", "r210", "r218" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r193" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r192" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r210" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r229" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r30", "r115", "r133" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "NON-CURRENT ASSETS" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current lease liabilities", "verboseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r44" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r32", "r116", "r133" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "NON-CURRENT LIABILITIES" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPortionOfNoncurrentLoansReceived", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Long-term loans, net of current maturities", "terseLabel": "Long-term loan, net of current maturities" } }, "en": { "role": { "documentation": "The non-current portion of non-current loans received. [Refer: Loans received]" } } }, "auth_ref": [ "r261" ] }, "blrx_NumberOfOrdinarySharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "NumberOfOrdinarySharesAbstract", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares.", "label": "Number Of Ordinary Shares [Abstract]", "verboseLabel": "Number of Ordinary Shares" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of other equity instruments exercisable" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Shares Authorised", "verboseLabel": "Authorized share capital (Shares)" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r68", "r97", "r118" ] }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssuedAndFullyPaid", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Shares Issued And Fully Paid", "verboseLabel": "Issued and paid-up share capital (Shares)" } }, "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } } }, "auth_ref": [ "r69", "r98", "r119" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "verboseLabel": "Other comprehensive loss" } } }, "auth_ref": [ "r34", "r105", "r123", "r126" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r262" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r137", "r144" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r202" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r165", "r175", "r185", "r216" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r168", "r178", "r188", "r219" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r168", "r178", "r188", "r219" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r191" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 40.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of lease liabilities", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r131" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r201" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r201" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r193" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r210" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r203" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r192" ] }, "blrx_PercentageOfCommissionOnSalesAgreement": { "xbrltype": "percentItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "PercentageOfCommissionOnSalesAgreement", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of commission on sales agreement.", "label": "Percentage of commission on sales agreement" } } }, "auth_ref": [] }, "blrx_PlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "PlacementAgentMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Placement Agent [Member]", "documentation": "placement agent [Member]" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r194" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r249" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r193" ] }, "blrx_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "PreFundedWarrantsMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Pre Funded Warrants [Member]", "documentation": "Pre Funded Warrants [Member]" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromCurrentBorrowings", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Proceeds from current borrowings", "verboseLabel": "Net proceeds from loan" } }, "en": { "role": { "documentation": "The cash inflow from current borrowings obtained. [Refer: Current borrowings]" } } }, "auth_ref": [ "r252" ] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r252" ] }, "blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds From Exercise Of Warrants After Deducting Fees And Expenses", "documentation": "Proceeds from exercise of warrants after deducting fees and expenses.", "terseLabel": "Proceeds from exercise of warrants after deducting fees and expenses" } } }, "auth_ref": [] }, "blrx_ProceedsFromExerciseWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ProceedsFromExerciseWarrants", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds From Exercise Warrants", "documentation": "The cash inflow from the exercise share purchase warrants.", "terseLabel": "Proceeds from exercise of warrants" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Net proceeds from transaction" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r252" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Issuance of share capital and warrants, net of issuance cost", "verboseLabel": "Gross proceeds", "terseLabel": "Issuance of share capital and warrants, net of issuance costs" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r130" ] }, "blrx_ProceedsFromWarrantIssue": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ProceedsFromWarrantIssue", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from warrant issue.", "label": "Proceeds From Warrant Issue", "verboseLabel": "Proceeds from warrant issue", "terseLabel": "Proceeds from warrant issue, net" } } }, "auth_ref": [] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Total fees" } } }, "auth_ref": [ "r261" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements", "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss", "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)", "totalLabel": "NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)", "verboseLabel": "Comprehensive income (loss) for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r25", "r27", "r58", "r60", "r81", "r88", "r104", "r122", "r133", "r136" ] }, "blrx_ProfitLossFromNonOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "ProfitLossFromNonOperatingActivities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "Non operating profit (loss) from operating activities of the entity.", "label": "Profit Loss From Non Operating Activities", "terseLabel": "NON-OPERATING INCOME (EXPENSES), NET", "verboseLabel": "NON-OPERATING EXPENSES, NET" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "OPERATING LOSS" } } }, "auth_ref": [ "r128", "r264" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r0", "r75", "r110" ] }, "ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative" ], "lang": { "en-us": { "role": { "label": "Provisions for doubtful debts related to outstanding balances of related party transaction", "terseLabel": "Provisions for doubtful debts" } }, "en": { "role": { "documentation": "The amount of provisions for doubtful debts related to the amount of outstanding balances in related party transactions. [Refer: Provisions]" } } }, "auth_ref": [ "r5", "r78" ] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of intangible assets", "label": "Purchase of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r129" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "negatedLabel": "Sale (purchase) of property and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r129" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r191" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r191" ] }, "blrx_RecognitionOfDayOneLossWithinProfitOrLossWarrantsMeasured": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "RecognitionOfDayOneLossWithinProfitOrLossWarrantsMeasured", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Recognition Of Day One Loss Within Profit Or Loss Warrants Measured", "documentation": "Amount of Day One loss recognized in profit or loss for warrants.", "terseLabel": "Recognition of Day One loss within profit or loss" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r160", "r170", "r180", "r211" ] }, "ifrs-full_RepaymentsOfCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfCurrentBorrowings", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of loan", "label": "Repayments of current borrowings" } }, "en": { "role": { "documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]" } } }, "auth_ref": [ "r252" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES", "label": "Research And Development Expense" } } }, "auth_ref": [ "r15", "r85" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r161", "r171", "r181", "r212" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r162", "r172", "r182", "r213" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r169", "r179", "r189", "r220" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition", "http://biolinerx.com/role/GENERALINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "verboseLabel": "Accumulated losses" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r138", "r145", "r146" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r107", "r141" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_GrossProfit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "REVENUES", "verboseLabel": "REVENUES", "totalLabel": "Total revenues" } } }, "auth_ref": [ "r33", "r51", "r57", "r59", "r63", "r64", "r65", "r124", "r133", "r139", "r140" ] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue [abstract]", "terseLabel": "REVENUES:" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromSaleOfGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromSaleOfGoods", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from sale of goods", "verboseLabel": "Product sales, net" } } }, "auth_ref": [ "r261" ] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets, net" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r43", "r45", "r66" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r229" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "SALES AND MARKETING EXPENSES", "label": "Sales And Marketing Expense" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "GENERAL AND ADMINISTRATIVE EXPENSES", "label": "Selling General And Administrative Expense" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpenseMember", "presentation": [ "http://biolinerx.com/role/SUPPLEMENTALFINANCIALINFORMATIONNarrative" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expense [member]", "terseLabel": "General and Administrative Expenses [Member]" } } }, "auth_ref": [ "r259", "r261" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r138", "r145" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share premium [Member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r107" ] }, "blrx_SharesIssuedRegisteredDirectOfferings": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "SharesIssuedRegisteredDirectOfferings", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Registered direct offerings sales.", "label": "Shares Issued Registered Direct Offerings", "verboseLabel": "Registered direct offerings sales", "terseLabel": "Registered direct offerings sales" } } }, "auth_ref": [] }, "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Short-term bank deposits" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r256" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r164", "r174", "r184", "r215" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "blrx_SupplementalInformationOnInterestPaidInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "SupplementalInformationOnInterestPaidInCash", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Supplemental information on interest paid in cash.", "label": "Supplemental information on interest paid in cash" } } }, "auth_ref": [] }, "blrx_SupplementalInformationOnInterestReceivedInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "SupplementalInformationOnInterestReceivedInCash", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Supplemental information on interest received in cash.", "label": "Supplemental information on interest received in cash" } } }, "auth_ref": [] }, "blrx_SupplementalInformationOnNonCashTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "SupplementalInformationOnNonCashTransactionsAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Supplemental Information On Non Cash Transactions [Abstract]", "verboseLabel": "Supplemental information on non-cash transactions:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r209" ] }, "blrx_TotalChangeInOperatingAssetAndLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "TotalChangeInOperatingAssetAndLiability", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Total Change in operating asset and liability.", "label": "Total Change In Operating Asset And Liability", "totalLabel": "Total Change in operating asset and liability" } } }, "auth_ref": [] }, "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "TotalIncomeAndExpenseNotInvolvingCashFlows", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Total income and expense not involving cash flows.", "label": "Total Income And Expense Not Involving Cash Flows", "totalLabel": "Total income and expense not involving cash flows" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r201" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r208" ] }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accruals:" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r143", "r263" ] }, "ifrs-full_TradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeReceivables", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade receivables", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } } }, "auth_ref": [ "r137", "r144" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r228" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r230" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r231" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r232" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r232" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r230" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r230" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r233" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r231" ] }, "ifrs-full_TypesOfInvestmentPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInvestmentPropertyAxis", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Types of investment property [axis]", "verboseLabel": "Types of investment property [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r261" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r227" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r197" ] }, "blrx_WarrantFourMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "WarrantFourMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Four [Member]", "documentation": "Warrant Four [Member]", "verboseLabel": "Warrant [Member]" } } }, "auth_ref": [] }, "blrx_WarrantIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "WarrantIssuanceCosts", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Warrant Issuance Costs", "documentation": "Warrant issuance costs.", "terseLabel": "Warrant issuance costs" } } }, "auth_ref": [] }, "blrx_WarrantOfferingConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "WarrantOfferingConsideration", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Offering Consideration", "documentation": "Tha amount of warrant offering consideration.", "terseLabel": "Warrants offering consideration" } } }, "auth_ref": [] }, "blrx_WarrantSixMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "WarrantSixMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Six [Member]", "documentation": "Warrant Six [Member]", "terseLabel": "Warrant [Member]" } } }, "auth_ref": [] }, "blrx_Warrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "Warrants", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition", "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "documentation": "The non-current portion of warrants.", "label": "Warrants", "verboseLabel": "Warrants", "periodStartLabel": "Opening Balance", "periodEndLabel": "Closing Balance" } } }, "auth_ref": [] }, "blrx_WarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "WarrantsExercised", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Exercised", "documentation": "Number of warrants exercised.", "terseLabel": "Warrants exercised" } } }, "auth_ref": [] }, "blrx_WarrantsExpirationPeriod": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "WarrantsExpirationPeriod", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants expiration period.", "label": "Warrants expiration period", "verboseLabel": "Warrants expiration period" } } }, "auth_ref": [] }, "blrx_WarrantsIssuedToPurchaseShares": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "WarrantsIssuedToPurchaseShares", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants issued to purchase shares.", "label": "Warrants issued to purchase shares" } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r250" ] }, "blrx_WarrantsReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "WarrantsReserve", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Represents amount related to warrant.", "label": "Warrants Reserve", "verboseLabel": "Warrants" } } }, "auth_ref": [] }, "blrx_WarrantsTerm": { "xbrltype": "durationItemType", "nsuri": "http://biolinerx.com/20250630", "localname": "WarrantsTerm", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants term.", "label": "Warrants Term", "terseLabel": "Warrants term" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Exercise price of other equity instruments exercisable" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "verboseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF EARNINGS (LOSS) PER ORDINARY SHARE" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r10" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r195" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_c&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "128", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_b&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_c&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "259", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "88", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r149": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r150": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r151": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r152": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r153": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r154": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r155": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r156": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r157": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r181": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r182": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r183": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r184": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r185": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r186": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r187": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r188": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r189": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r190": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r191": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r192": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r193": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r194": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r195": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r196": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r197": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r198": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r199": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r200": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r201": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r202": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r203": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r204": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r205": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r206": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r207": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r208": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r209": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r210": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r211": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r212": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r213": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r214": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r215": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r216": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r217": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r218": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r219": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r220": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r221": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r222": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r223": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r224": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r225": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r226": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r227": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r237": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r238": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r239": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r240": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r241": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r242": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r243": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r244": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r245": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r246": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r247": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r248": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r249": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }